Actual Treatment Options for Giant Cell Arteritis

Journal article


Publication Details

Author(s): Moosig F, Schmalzing M, Aries PM, Henes J, Lamprecht P, Rech J, Witte T
Journal: Deutsche Medizinische Wochenschrift
Publication year: 2019
Volume: 144
Journal issue: 9
Pages range: 595-600
ISSN: 0012-0472
eISSN: 1439-4413


Abstract

To prevent serious complications such as permanent loss of vision and structural vascular damage, treatment must be initiated quickly in patients with giant-cell arteritis (GCA). So far, usually long-term corticosteroids in cumulative high dosages have been the standard therapy option. However, steroids are often insufficient to achieve adequate disease control and are associated with serious adverse events. Therefore, steroid-sparing therapy options are the focus of interest.


External institutions with authors

Medizinische Hochschule Hannover (MHH) / Hannover Medical School
PRI Pediatric Rheumatology Research Institute GmbH
Universitätsklinikum Schleswig-Holstein (UKSH)
Universitätsklinikum Tübingen
Universitätsklinikum Würzburg


How to cite

APA:
Moosig, F., Schmalzing, M., Aries, P.M., Henes, J., Lamprecht, P., Rech, J., & Witte, T. (2019). Actual Treatment Options for Giant Cell Arteritis. Deutsche Medizinische Wochenschrift, 144(9), 595-600. https://dx.doi.org/10.1055/a-0832-3563

MLA:
Moosig, Frank, et al. "Actual Treatment Options for Giant Cell Arteritis." Deutsche Medizinische Wochenschrift 144.9 (2019): 595-600.

BibTeX: 

Last updated on 2019-01-08 at 14:04